Harrow (HROW) Competitors

Definium Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Harrow has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

In the previous week, Definium Therapeutics had 13 more articles in the media than Harrow. MarketBeat recorded 20 mentions for Definium Therapeutics and 7 mentions for Harrow. Harrow's average media sentiment score of 0.44 beat Definium Therapeutics' score of 0.32 indicating that Harrow is being referred to more favorably in the news media.

Harrow has higher revenue and earnings than Definium Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Definium Therapeutics currently has a consensus target price of $64.88, suggesting a potential upside of 75.15%. Harrow has a consensus target price of $66.17, suggesting a potential upside of 118.21%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Definium Therapeutics.

Definium Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Definium Therapeutics' return on equity.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Harrow currently has a consensus price target of $66.17, suggesting a potential upside of 118.21%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 27.07%. Given Harrow's higher probable upside, equities research analysts clearly believe Harrow is more favorable than Indivior.

In the previous week, Harrow had 5 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Harrow and 2 mentions for Indivior. Harrow's average media sentiment score of 0.44 beat Indivior's score of 0.00 indicating that Harrow is being referred to more favorably in the media.

Harrow has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Indivior has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Indivior has a net margin of 26.65% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Indivior's return on equity.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organon & Co. has a net margin of 3.41% compared to Harrow's net margin of -13.51%. Organon & Co.'s return on equity of 88.97% beat Harrow's return on equity.

Harrow has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Harrow presently has a consensus target price of $66.17, suggesting a potential upside of 118.21%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 16.88%. Given Harrow's stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Organon & Co..

Organon & Co. has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

In the previous week, Harrow had 3 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Harrow and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.60 beat Harrow's score of 0.44 indicating that Organon & Co. is being referred to more favorably in the news media.

In the previous week, Harrow had 6 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Harrow and 1 mentions for Arcutis Biotherapeutics. Harrow's average media sentiment score of 0.44 beat Arcutis Biotherapeutics' score of 0.42 indicating that Harrow is being referred to more favorably in the media.

Harrow has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Harrow currently has a consensus target price of $66.17, suggesting a potential upside of 118.21%. Arcutis Biotherapeutics has a consensus target price of $35.57, suggesting a potential upside of 40.91%. Given Harrow's higher possible upside, equities research analysts plainly believe Harrow is more favorable than Arcutis Biotherapeutics.

Harrow has higher earnings, but lower revenue than Arcutis Biotherapeutics. Harrow is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Harrow's net margin of -13.51%. Arcutis Biotherapeutics' return on equity of 15.05% beat Harrow's return on equity.